儿童弥漫性软脑膜胶质神经元肿瘤的高级别特征:与典型低级别病例对比
该文报告2例儿童弥漫性软脑膜胶质神经元肿瘤(DLGNT),1例为典型低级别、经化疗成功管理,另1例初诊即见间变和核分裂指数升高,放化疗后初始有效但最终致死。DLGNT通常低级别,可伴BRAF重排/重复、BRAF V600E突变及1p缺失等遗传学改变。
要点
- DLGNT通常为低级别,但少数病例可表现间变和核分裂指数升高等高级别特征。
- DLGNT可伴BRAF重排/重复、BRAF V600E突变及1p缺失等遗传学改变。
- 高级别特征的DLGNT即使初始对放化疗有反应,仍可能致命。
核心结论
- DLGNT多数为低级别且病程惰性,但少数病例初诊即表现间变和核分裂指数升高等高级别特征,预后差。
研究设计与样本
- 病例报告,对比2例儿童DLGNT:1例典型低级别,1例初诊即见高级别特征。
主要发现
- 低级别病例病程惰性但非良性,目前经化疗成功管理。
- 高级别病例初诊见明显间变和核分裂指数升高,放化疗初始有效但最终致死。
- DLGNT可伴BRAF重排/重复(高达75%)、BRAF V600E突变(较小亚群)及1p缺失(约50%-60%),其中约20%见1p/19q共缺失。
关键数值与推荐
- BRAF重排/重复见于高达75%的DLGNT病例。
- 1p缺失见于约50%-60%的DLGNT病例,其中约20%见1p/19q共缺失。
临床怎么用
- 儿童DLGNT诊断需结合影像和病理,注意识别间变和核分裂指数升高等高级别特征。
- 对高级别特征的DLGNT应警惕其潜在致死性,即使初始放化疗有反应。
局限性
- 仅2例病例报告,结论的外推受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse leptomeningeal glioneuronal tumor, a recent addition to the World Health Organization classification system, typically presents in the pediatric population with signs and symptoms related to elevated intracranial pressure and imaging characteristics that may mimic infectious etiologies. The tumor is usually low grade and tends to harbor BRAF rearrangement/duplication in up to 75% of cases, BRAF V600E mutation in a smaller subset of cases, and loss of chromosomal arm 1p in approximately 50%-60% of cases, with ~20% of those showing loss of both 1p and 19q (codeletion). We report here 2 contrasting cases of diffuse leptomeningeal glioneuronal tumors, one with typical low-grade features and an indolent, although not benign, course, in which the disease is currently successfully managed by chemotherapy, and a second case with unusually high-grade features on initial presentation, including frank anaplasia and elevated mitotic index, in which the disease showed an initial response to chemoradiation but ultimately was fatal.
引用
- Schwetye KE, Kansagra AP, McEachern J, et al. Unusual high-grade features in pediatric diffuse leptomeningeal glioneuronal tumor: comparison with a typical low-grade example. Hum Pathol. 2017. PMID: 28652147. doi:10.1016/j.humpath.2017.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。